Astellas Pharma, Inc.
) recently announced the launch of its overactive bladder (OAB)
drug, Betmiga (mirabegron), in the UK.
Betmiga had gained EU approval for the treatment of OAB
symptoms in adults in Jan 2013. We note that Astellas' Betmiga is
already approved in the US where it is available under the trade
name, Myrbetriq. It is also approved in Japan under the trade
We are encouraged by the UK launch of Betmiga. The drug will
be available throughout Europe as part of the launch plan.
According to information provided by Astellas, OAB affects around
7 million adults in the UK.
According to information provided by Astellas, OAB is
estimated to affect more than 400 million people globally.
According to a population-based prevalence study, 17% of men and
women are affected by OAB in Europe with the prevalence
increasing to 30-40% in people above 75 years of age.
Betmiga is the first once daily oral β3-adrenoceptor agonist
to be approved for the treatment of OAB. Betmiga has a different
mechanism of action compared to antimuscarinics, which are the
current standard of treatment.
Results on Betmiga showed that it improves the storage
capacity of the bladder without inhibiting bladder voiding. Thus,
it has the ability to decrease the urge to urinate and leads to
lower incontinence episodes. It has lower side effects as well.
This should help Betmiga capture a significant share of the OAB
Currently approved OAB treatments include
) Enablex and
Astellas carries a Zacks Rank #4 (Sell). Right now
Lannett Company, Inc.
) looks more attractive with a Zacks Rank #1 (Strong Buy).
ASTELLAS PHARMA (ALPMY): Get Free Report
LANNETT INC (LCI): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
WARNER CHIL PLC (WCRX): Free Stock Analysis
To read this article on Zacks.com click here.